Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder
NCT07304960
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
View Trial DetailsNCT Number: NCT06770959
The aim of this work is to identify different pattern of Gastrointestinal and Hepatic symptoms and its Frequency among patients with Multiple Sclerosis
Trial opening soon.
Get NotifiedAll sexes
Observational
Historically, the routine evaluation of symptoms in MS patients focused on skeletal muscle impairments that restricted mobility. Within the last two decades, symptoms such as dysphagia, bladder and bowel dysfunction, among others, have been increasingly recognized and incorporated into patient assessments [1-3]. The GI problems felt to be most common in MS patients involve deglutition and defecation and require volitional muscle coordination. This association may link the development of such GI problems to underlying MS disease progression. However, GI symptoms that are not dependent upon skeletal muscle control are common in the general population and may also be present in MS patients. More than two decades ago, Hinds and colleagues described a high prevalence of anorectal dysfunction in a large cohort of MS patients [4]. Since then, the diagnostic and clinical approach to MS care has changed dramatically and now emphasizes the early introduction of disease modifying therapies [5]. However, despite changes in MS care, anorectal dysfunction and swallowing problems continue to be an important problem for MS patients . Little is known about other GI symptoms in MS patients in this new era of pervasive use of disease modifying therapies. To address this gap in knowledge, the investigators sought to define the prevalence of GI symptoms and syndromes in a large sample of contemporary MS patients
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
3- Pt with MS suffer from git and hepatic symptoms not explained by known cause as Hepatitis virus،metabolic disorders as Wilson . hemochromatosis,etc Drug induced , Alcohol , Git symptoms as dysphagia, vomiting,reflux
4- An informed consent will be obtained from all the patients, the study will be approved by ethical committee in faculty of Medicine Assiut University
Exclusion criteria
1-patients already diagnosed with other GIT disorders before diagnosis of MS
2_ Presence of other disorder or on medications that may affect the neurological or GIT disorders.
3_ Patients failed to commit to the follow up visits and regular MRI scans 4_ Patients refused to sign the written informed consent Patients who will meet the inclusion and exclusion criteria will be assessed in the 1st visit by direct interview followed by clinical examination and neuropsychological assessments. Baseline MRI scans will be obtained at the first visit
-
Time frame: 24 month
Contact information is provided by the study sponsor or research team.
Nayera Mohamed Refaat, master degree
CONTACT
Shady Mohamed Safwat, doctor
CONTACT
Assiut University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07304960
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
View Trial DetailsNCT06782724
ALS (Amyotrophic Lateral Sclerosis), Amyotrophic Lateral Sclerosis
Prague, Czechia
View Trial DetailsNCT07521384
Alzheimer Dementia (AD), Alzheimer Disease
Monterrey, Nuevo León, Mexico
View Trial DetailsNCT07202195
Ataxia, Ataxia - Other
Steenokkerzeel, Belgium
View Trial Details